

Product Information

SILu™Lite AKT2, RAC-beta serine/threonine-protein kinase, human recombinant, expressed in HEK 293 cells MS Protein Standard

Catalog Number **MSST0052**
Storage Temperature $-20\text{ }^{\circ}\text{C}$

Synonyms: Protein kinase Akt-2, Protein kinase B beta (PKB beta), Proto-oncogene c-Akt, RAC-PK-beta

Product Description

SILu™Lite AKT2 is a recombinant human protein expressed in human 293 cells. It consists of 502 amino acids, with a calculated molecular mass of 58.29 kDa (including N-terminal polyhistidine and FLAG® tags). SILu™Lite AKT2 is an analytical standard designed to be used as starting material for preparation of calibrators and controls in LC-MS applications.

AKT2 is a serine/threonine kinase that is a member of the AKT family. AKT2, like the other AKT members, is activated in cells in response to diverse stimuli such as hormones, growth factors, and extracellular matrix components.¹ Once activated by phosphorylation at Ser⁴⁷⁴ and Thr³⁰⁹, AKT2 is involved in glucose metabolism, transcription, survival, cell proliferation, angiogenesis, and cell motility.² AKT2 seems to be the principal isoform responsible in the regulation of the insulin signaling pathway.³

Overexpressed phospho-AKT is frequently observed in human lung, gastric, hepatocellular, pancreatic, renal, prostate, and endometrial cancer as well as multiple myeloma.⁴⁻⁵ The aggressiveness of several types of solid tumors and hematologic malignancies is linked to the deregulation of AKT and its upstream signaling partners. Members of the AKT pathway are therefore potential targets for novel anti-cancer therapeutics.⁶

Each vial contains 50 µg of SILu™Lite AKT2 standard in a solution of phosphate buffered saline with 1 mM EDTA and 25% glycerol. Vial content was determined by the Bradford method using BSA as a calibrator.

Purity: $\geq 95\%$ (SDS-PAGE)

UniProt: P31751

Sequence Information:

The N-terminal polyhistidine and FLAG® tags are italicized.

MDYKDDDDKGGHHHHHHHGGQMNEVSVIKEGWLH
KRGEYIKTWRPRYFLLKSDGSFIGYKERPEAPDQTL
PLNNSVAECQLMKTERPRPNTFVIRCLQWTTVIERT
FHVDSPPEREEWMRAIQMVANSLKQRAPGEDPMDY
KCGSPSDSSTTEEMEVAVSKARAKVTMNDFDYLKLL
GKGTFGKIVLREKATGRYYAMKILRKEVIAKDEVAH
TVTESRVLQNTRHPFLTALKYAFQTHDRLCFVMEYAN
GGELFFHLSRERVFTEERARFYGAEIVSALEYLHSRD
VVYRDIKLENLMLDKDGHKIDTDFGLCKEGISDGATMK
TFCGTPEYLAPEVLEDNDYGRAVDWWGLGVVMYEM
MCGRLPFYNQDHERL FELILMEEIRFPRTL SPEAKSLL
AGLLKDPKQRLGGGSPDAKEVMEHRFFLSINWQDV
VQKLLPPFKPQVTSEVDTRYFDDEFTAQSITITPPDR
YDSLGLLELDQRTHFPQFSYSASIRE

Precautions and Disclaimer

This product is for R&D use only, not for drug, household, or other uses. Please consult the Safety Data Sheet for information regarding hazards and safe handling practices.

Storage/Stability

Store the product at $-20\text{ }^{\circ}\text{C}$. The product retains its concentration for at least 2 years as supplied. After initial thawing it is recommended to store the protein in working aliquots at $-20\text{ }^{\circ}\text{C}$.

References

1. Alessi, D.R., and Cohen, P., Mechanism of activation and function of protein kinase B. *Curr. Opin. Genet. Dev.*, **8(1)**, 55-62 (1998).
2. Coffey, P.G. et al., Protein kinase B (c-Akt): a multifunctional mediator of phosphatidylinositol 3-kinase activation. *Biochem. J.*, **335(1)**, 1-13 (1998).
3. Ng, Y. et al., Rapid activation of Akt2 is sufficient to stimulate GLUT4 translocation in 3T3-L1 adipocytes. *Cell metabolism*, **7(4)** 348-356 (2008).
4. Altomare, D.A., and Testa, J.R., Perturbations of the AKT signaling pathway in human cancer. *Oncogene*, **24(50)**, 7455-7464 (2005).
5. Cicens, J., The potential role of Akt phosphorylation in human cancers. *Int. J. Biol. Markers*, **23(1)**, 1-9 (2008).
6. Garcia-Echeverria, C., and Sellers, W.R., Drug discovery approaches targeting the PI3K/Akt pathway in cancer. *Oncogene*, **27(41)**, 5511-5526 (2008).

SILu is a trademark of Sigma-Aldrich Co. LLC.
FLAG is a registered trademark of Sigma-Aldrich Co. LLC.

JK,MAM 05/17-1